Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer.

Oncotarget - 20 Jan 2015

Vujic Igor, Sanlorenzo Martina, Posch Christian, Esteve-Puig Rosaura, Yen Adam J, Kwong Andrew, Tsumura Aaron, Murphy Ryan, Rappersberger Klemens, Ortiz-Urda Susana

Abstract excerpt

Attempts to directly block the mutant neuroblastoma rat sarcoma oncogene (NRAS) protein, a driving mutation in many cancer types, have been unsuccessful. Current treatments focus on inhibition of different components of NRAS' two main downstream cascades: PI3K/AKT/mTOR and MAPK. Here we test a novel dual therapy combination of metformin and trametinib on a panel of 16 NRAS mutant cell lines, including melanoma...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to TOR Serine-Threonine Kinases
Share to Drug Synergism

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to GTP Phosphohydrolases

Share to Metformin

Share to Pyridones

Share to Pyrimidinones

Share to Tumor Burden

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 25504439
DOI: 10.18632/oncotarget.2824
PMCID: PMC4359268

Genes

NRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer.PMID 25504439Read ↗

Mutant NRASQ61 shares signaling similarities across various cancer types--potential implications for future therapies.Semantic proximity Read ↗

Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.Semantic proximity Read ↗

Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma.Semantic proximity Read ↗

Cooperative induction of apoptosis in NRAS mutant melanoma by inhibition of MEK and ROCK.Semantic proximity Read ↗

Effect of Metformin in Combination With Trametinib and Paclitaxel on Cell Survival and Metastasis in Melanoma Cells.Semantic proximity Read ↗

Targeting the MAPK pathway for NRAS mutant melanoma: from mechanism to clinic.Semantic proximity Read ↗

Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma.Semantic proximity Read ↗

A screen for combination therapies in <i>BRAF/NRAS</i> wild type melanoma identifies nilotinib plus MEK inhibitor as a synergistic combinationSemantic proximity Read ↗

A novel combination treatment against melanoma with NRAS mutation and therapy resistance.Semantic proximity Read ↗

MicroRNA-708 emerges as a potential candidate to target undruggable NRAS.Semantic proximity Read ↗

Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS-mutant melanoma.Semantic proximity Read ↗

Combined blockade of polo-like kinase and pan-RAF is effective against NRAS-mutant non-small cell lung cancer cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.